~~<i id='2EC451EE52'><strike id='2EC451EE52'><tt id='2EC451EE52'><pre id='2EC451EE52'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：leisure time 2025-10-01 04:32:42 - browse：894

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： Opioid cravings were reduced by anti

focus

knowledge

hotspot

focus

Wikipedia

entertainment

AdobeArecentstudypromptedCNNtoreport,“Mostcancerscreeningsdon’tultimatelygivesomeoneextratimebeyondt

WSS

Advances in CAR

Opioid cravings were reduced by anti

How generative AI is inspiring dreams of a health data revolution

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

The (many) problems with a new study criticizing cancer screening

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

focus

knowledge

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Illumina names Agilent executive as new CEO

Moonlake's readout produced a cash windfall. Risks remain

The 10 drugs up first for Medicare price negotiation

The high cost of giving birth even with insurance

Humana sues Biden admin over Medicare Advantage audit rule

After affirmative action ruling, medical educators look to 'holistic review'

ALS advocates say criticism of new drugs misses bigger picture

How one medical school became remarkably diverse

Trump surgeon general acknowledges mistakes during Covid

knowledge

What American doctors can learn from their Israeli counterparts

Stem cell treatment guidelines are released by FDA

Secretariat’s lessons for human medicine

Measles policy set amid Florida outbreak alarms vaccine proponents

House transparency, PBM reform bill gains bipartisan support

The 10 drugs up first for Medicare price negotiation

hotspot

focus

Wikipedia

entertainment